Free Trial
→ Why this tiny stock may move before the SpaceX IPO drops (From Behind the Markets) (Ad)tc pixel
NASDAQ:TNFA

TNF Pharmaceuticals Q2 2025 Earnings Report

TNF Pharmaceuticals logo
$3.87 +0.05 (+1.31%)
As of 06/12/2026
ProfileEarnings HistoryForecast

TNF Pharmaceuticals EPS Results

Actual EPS
-$18.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

TNF Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TNF Pharmaceuticals Announcement Details

Quarter
Q2 2025
Date
8/19/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

TNF Pharmaceuticals Earnings Headlines

TNF Pharmaceuticals (NASDAQ:TNFA) Stock Price Up 1.9% - What's Next?
June 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30830166
Why did QCLS stock surge over 60% today?
December 4, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/why-did-qcls-stock-surge-over-60-today/ar-AA1RJkpU
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.tc pixel
June 15 at 1:00 AM  |  Weiss Ratings (Ad)
Rheumatoid Arthritis Market to Surge by 2034 as Next-Generation Biologics and JAK Inhibitors Gain Traction | DelveInsight
November 5, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/rheumatoid-arthritis-market-surge-2034-223100043.html
Forward Therapeutics Announces First Participants Dosed in Phase 1 Healthy Volunteer Study of FT2109, a Next-Generation TNF Signaling Inhibitor
October 30, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/forward-therapeutics-announces-first-participants-dosed-in-phase-1-healthy-volunteer-study-of-ft2109-a-next-generation-tnf-signaling-inhibitor-1035455199
Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS"
September 26, 2025  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2025/09/25/10260815.htm
See More TNF Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TNF Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TNF Pharmaceuticals and other key companies, straight to your email.

About TNF Pharmaceuticals

TNF Pharmaceuticals (NASDAQ:TNFA) operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

View TNF Pharmaceuticals Profile
Earnings Tools